all cause mortality; cancer chemotherapy; cancer therapy; computer assisted tomography; coronavirus disease 2019/dt [Drug Therapy]; disease severity; drug efficacy; drug safety; editorial; human; India; length of stay; lockdown; lymphocytopenia; malignant neoplasm; morbidity; mortality; mortality rate; multiple myeloma; pandemic; perception test; real time reverse transcription polymerase chain reaction; retrospective study; risk assessment; C reactive protein/ec [Endogenous Compound]; rituximab/dt [Drug Therapy]